Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Sunday 30 August →